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Abstract
Background: The aim was to develop and validate the quality of life scale for nasopharyngeal carcinoma (NPC)
patients, the QOL-NPC (version 2), a specific instrument to measure quality of life for NPC patients.
Methods: The QOL-NPC was developed and validated according to standard procedures. The patients were
assessed using the QOL-NPC, FACT-G, and FACT-H&N. Classical test theory was used to evaluate the reliability,
validity, and responsiveness of the QOL-NPC.
Results: A total of 487 patients (97.4 %) completed the questionnaire. The QOL-NPC comprised four domains, as
follows: physical function (eight items); psychological function (five items); social function (five items); and side
effects (eight items). All of the items had a lower proportion of missing data. Cronbach's alpha values of the
domains ranged from 0.72 to 0.84. The split-half reliability coefficients ranged from 0.77 to 0.84. All of the intra-class
correlation coefficients were > 0.8. The normed fit index, non-normed fit index, and comparative fit index were >0.89.
The root mean square error of approximation was 0.097, with a 90 % confidence interval (0.093, 0.100). The domain
scores of the QOL-NPC were significantly correlated with the FACT-G and FACT-H&N (P < 0.05). All of the domain
scores of patients using different amounts of radiotherapy were significantly different (P < 0.001). All domain scores
decreased at the completion of radiotherapy, with effect sizes ranging from −0.82 to −0.22.
Conclusions: The QOL-NPC is valid for measuring QOL with good reliability, validity, and responsiveness. The QOL-NPC
is recommended to measure the QOL for Chinese NPC patients.
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Background
Nasopharyngeal carcinoma (NPC) is a malignancy with
a high incidence in several geographic areas, especially
southern China and Hong Kong [1, 2]. Because NPC is
located in close proximity to the base of the skull and is
sensitive to radiotherapy (RT), the primary treatment is
RT alone or combined with chemotherapy [3, 4]. RT
causes various side effects, such as xerostomia, dyspha-
gia, and hearing loss. These side effects obviously have a
serious impact on the health-related quality of life
(QOL) in NPC patients. The QOL of the NPC patients
has been widely studied with the following inventories:
the European Organization for the Research and Treat-
ment of Cancer Core QOL questionnaire (QLQ-C30)
and head and neck module (QLQ-H&N35) [4, 5]; the
MOS 36-item short-form health survey (SF-36) [6, 7];
The University of Washington Quality of Life [8]; the
Functional Assessment of Cancer Therapy-General Scale
(FACT-G) and head and neck module (FACT-H&N) [9,
10]; and the functional assessment of cancer therapy-
nasopharyngeal (FACT-NP) [11].
The quality of life scale of nasopharyngeal carcinoma
patients (QOL-NPC, version 1 [V1]) is an NPC-specific
scale, which was used to assess the physical functioning
and health status of the NPC people in the past 2 weeks
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[12–14]. The QOL-NPC was widely used to evaluate the
QOL of Chinese NPC patients. Based on the application
there were some problems. (1) The item of the QOL-
NPC (V1) was rated on a 0–10 numeric visual analogue
scale (VAS). Some patients reported that it was difficult
to understand. For example, some patients with poorer
reading skills were not able to distinguish score 5 from
score 6. Most studies have reported that VAS and Likert
responses have few differences in reliability and re-
sponsiveness, and are highly correlated [15–17]. Be-
cause the Likert responses are easier to administer,
compute, and interpret for the patients, Likert re-
sponses are most often applied [15–18]. (2) Some
items had problems. The previous patients reported
that they were worried about the infection of the
disease due to a lack of medical knowledge. There-
fore, the item “worried about the infection of the
disease” was applied in V1. Some important symp-
toms were missing in V1, such as pain in the throat
and cough when swallowing food.
The purpose of this study was to develop and assess
the QOL-NPC (version 2 [V2]) according to a set of
standardized procedures of instrument development.
Methods
Development of the QOL-NPC
The standard development and validation procedures
were followed to develop and validate the QOL-NPC
[19–23]. The procedures are shown in Fig. 1, which
included construct definition, item generation, language
testing and content validity, pilot study, and validation
study.
Construct definition and item generation
The QOL-NPC (V1) contains 30 items in four domains:
physical function (PH, seven items); psychological func-
tion (PS, six items); social function (SO, five items); and
side effect (SE, 12 items).
The domains of the QOL-NPC (V2) were sourced
from V1. The items of the V1 were carefully discussed
and revised by five experts. For example, the item
“worried about the infection of the disease” was revised
to “worried about the inheritance of the disease.” Ac-
cording to suggestions from NPC patients and clinical
professionals, the following three items were added: have
a pain in your throat (PH domain); cough when swal-
lowing food (PH domain); and feel difficult to communi-
cate with your family and friends (SO domain). Finally, a
total of 33 items were generated. The VAS scale of the
item was revised into a 1–5 Likert scale. The 1–5 Likert
scales were expressed as not at all (excellent), a little bit
(very good), moderate (good), quite a bit (fair), and ex-
treme (poor).
Language testing and content validity
All of the items were tested in a convenience sample of
20 NPC patients from different educational levels. The
patients were asked whether or not they could under-
stand the meaning of the items. Problematic items were
revised according to the comments of the patients.
Fig. 1 Steps towards development and validation procedure
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Eight experts were asked to assess the content validity.
Expert consulting was available to evaluate whether or
not the items of the QOL-NPC could represent the most
relevant and important aspects of NPC patients [24].
Minor revisions and rewording of some items were per-
formed until content validity was achieved.
Pilot testing
A cross-sectional study (pilot testing) was conducted to
select the items. A total of 181 NPC patients were
enrolled. The Research Ethics Committee of the Cancer
Center at Sun Yat-Sen University provided ethical ap-
proval. The sample size was 5–10 times the item num-
ber for the pilot test. The items were screened and
selected using the floor and ceiling method, coefficient
of variation, correlation analysis, internal consistency co-
efficients, and confirmatory factor analysis. According to
item selection, seven items were deleted, five of which
were deleted from the SE domain. Due to the popularity
of intensity-modulated radiotherapy (IMRT), the NPC
patients had fewer side effects, such as dysphonia, alope-
cia (hair loss), dizziness, and decreased vision due to RT.
After the item selection, the QOL-NPC (V2) contained
26 items in four domains: PH (eight items); PS (five
items); SO (five items); and SE domain (eight items).
Each item scored 1 to 5 points. Each domain was trans-
formed into a 0–100 score. A higher score indicated a
better QOL. The scale was self-administered by the pa-
tients. The scale was showed in Appendix 1.
Validation study
A cross-sectional study (validation study) was conducted
to assess the psychological characteristics of the QOL-
NPC V2. The Research Ethics Committee of the Cancer
Center at Sun Yat-Sen University provided ethical ap-
proval. The study was conducted between 1 July 2013
and 31 May 2014. Eligibility criteria included the follow-
ing: (1) pathologically-proven NPC in the Cancer Center
of Sun Yat-Sen University; (2) ≥16 years of age; and (3)
able to provide informed consent to participate. The pa-
tients were excluded if diagnosed with another cancer,
NPC relapse, or unconscious, confused, or cognitively
impaired. The cognitively impaired were diagnosed by a
psychologist.
The investigators included two medical post-graduates
and three physicians, who were trained before the sur-
vey. The investigators explained the aim of our study be-
fore obtaining informed consent from the patients. If the
patients agreed to participate in the survey, a question-
naire was given to them. The questionnaire included a
socio-demographic sheet, QOL-NPC V2, FACT-G,
and FACT-H&N. The socio-demographic sheet cov-
ered gender, educational degree, marriage status, dia-
lect (Cantonese, Hakka, Chaoshanese, and others),
pathologic type, Union for International Cancer Con-
trol (UICC) stage, methods of RT, RT stage, and other
disease. The patients completed the questionnaire
without assistance. If the patients did not understand
the items on the questionnaire, the investigators ex-
plained them. If the questionnaire had missing data,
the questionnaire was immediately returned to the
patient for completion.
Terwee et al. considered a sample size of at least 50
patients to be adequate for the assessment of retest reli-
ability and responsiveness [25]. Eighty inpatients were
required to complete the QOL-NPC V2 within 2–3 days,
which was used for the retest-test. A short interval (2–3
days) was chosen for the following reasons: (1) The NPC
in-patients were all treated with RT, which had an obvi-
ous influence on QOL, especially for the long interval.
(2) Marx et al. reported no significant differences for the
test-retest reliability of 2 day and 2 week intervals [26].
The newly-diagnosed patients (60 patients), who had not
been previously treated by RT, were required to finish
the QOL-NPC after 50 ± 2 days of RT treatment. The
data were used for the responsiveness test. These pa-
tients completed the scale by themselves in the retest
and responsiveness tests. The investigators, the setting
environment, and the investigation procedure were the
same as the first test.
Data analysis
Classical test theory (CTT) was used to assess the scale.
SPSS 21.0 (Chicago, IL, USA) and Lisrel software (ver-
sion 8.7) were performed [27]. The percentage of miss-
ing data, and the time to complete the instrument was
calculated. Internal consistency reliability and split-half
reliability were assessed using Cronbach's alpha value
and Pearson's correlation coefficients between two
halves of the items, respectively. Test-retest reliability
was evaluated using an intra-class correlation coefficient
(ICC) and the 95 % confidence interval (CI) of the two
scores within 2–3 days. The correlation coefficients of
the item-own domain (the item and its own domain)
and the item-other domains (the item and other do-
mains) were calculated. Construct validity was evaluated
by the normed fit index (NFI), non-normed fit index
(NNFI), comparative fit index (CFI), and root mean
square error of approximation (RMSEA) based on con-
firmatory factor analysis (CFA) [28–30]. The correlation
coefficients between the QOL-NPC and the FACT
(FACT-G and FACT-H&N) were calculated to assess cri-
terion validity. Discriminant validity was assessed by
comparing the domain scores of the patients among dif-
ferent RT stages and different RT methods (analysis of
variance). A paired samples t-test was used to analyze
the score changes over time. Effect size was calculated
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as the change in scores divided by the standard deviation
of the baseline score [31].
Results
A sample of 500 patients was enrolled in the study.
Thirteen patients (2.6 %) did not complete the question-
naire. Thus, 487 patients were included for the analysis
(Table 1). The mean age was 47.0 ± 11.1 years (range,
16.1–78.1 years). There were 341 male and 146 female
patients. Of the patients, 93.0 % were married, 68.8 %
were Cantonese, 88.9 % were the undifferentiated type,
46.6 % were III stage, and 79.9 % did not have another
disease.
The average time to complete the instrument was
8.4 ± 4.6 min, ranging from 3.8 to 16.3 min. Ten pa-
tients did not understand certain items, such as the
item “mental stress”. They completed the items with
the help of the investigators. The scores of all the
items ranged from 1 to 5 (Table 2). Item SE8 scored
the highest (3.90), while item PS2 scored the lowest
(2.46). Item SE8 had 3.7 % missing data. Other items
had a lower proportion of missing data.
The mean score of the SE domain was the maximum
(64.5), and the mean score of the PS domain was the
minimum (50.3; Table 3). The Cronbach's alpha value of
the domain ranged from 0.72 to 0.84. The split-half coef-
ficients of the domain ranged from 0.77 to 0.84. The SE
domain had a maximum Cronbach's alpha value and
split-half coefficient. All of the ICCs were >0.8, and of
all the coefficients were significantly different.
All items correlated more strongly with their own do-
main than the other domains (Table 4). For example, the
correlation coefficients of the items in the PH domain
and PH ranged from 0.47 to 0.77, which were greater
than the other domains.
The results of the CFA analysis showed that the
RMSEA was equal to 0.097 with a 90 % CI (0.093,
0.100). Both the NFI and NNFI were equal to 0.89.
The CFI was equal to 0.90. The factor loadings of
CFA are shown in Table 4. The minimum factor load-
ing was 0.47 (SO1 and SO2). The structure diagram
is shown in Fig. 2.
The PH, PS, and SO domains of the QOL-NPC had a
positive correlation with physical, emotional, and social/
family well-being of the FACT-G with coefficients of
0.71, 0.63, and 0.56, respectively. The correlation coeffi-
cient between the SE domain of the QOL-NPC and
FACT-H&N was 0.51, which was significantly different.
The PH, PS, and SE domain scores of patients in dif-
ferent RT stages were significantly different (P <0.001;
Table 5). The patients who were receiving RT had the
lowest scores in the PH, PS, and SE domains. The pa-
tients before RT and >5 years after RT had the highest
scores. The SO domain scores of patients in different RT
stages were not significantly different (P >0.05). All the
domain scores of patients using different RT methods
were significantly different (P <0.001; Table 5). The pa-
tients who did not receive RT had the highest scores,
followed by those receiving intensity-modulated radio-
therapy (IMRT).
Sixty patients before RT were enrolled to test the
responsiveness of the QOL-NPC over time. At the
Table 1 Characteristics of the patients
Number
(%, n = 487)
Number
(%, n = 80)a
Number
(%, n = 60)b
Gender
Male 341 (70.0) 58 (72.5) 43 (71.7)
Female 146 (30.0) 22 (27.5) 17 (28.3)
Educational degree
≤9 years 272 (55.9) 60 (75.0) 45 (75.0)
~12 years 180 (37.0) 14 (17.5) 12 (20.0)
>12 years 35 (7.2) 6 (7.5) 3 (5.0)
Marriage stage
Unmarried 34 (7.0) 12 (15.0) 9 (15.0)
Married 453 (93.0) 68 (85.0) 51 (85.0)
Dialect
Cantonese 335 (68.8) 53 (66.3) 38 (63.3)
Hakka 87 (17.9) 14 (17.5) 12 (20.0)
Chaoshanese 48 (9.9) 5 (6.3) 5 (8.3)
Others 17 (3.5) 8 (10.0) 5 (8.3)
Source of the patients
In-patients 80 (16.4) 80 (100.0) 60 (100.0)
Out-patients 407 (83.6) 0 (0.0) 0 (0.0)
Pathological type
Squamous cell 22 (4.5) 6 (7.5) 5 (8.3)
Differentiation type 32 (6.6) 9 (11.3) 5 (8.3)
Undifferentiated type 433 (88.9) 65 (81.3) 50 (83.3)
UICC stage
I stage 22 (4.5) 0 (0.0) 0 (0.0)
II stage 78 (16.0) 12 (15.0) 4 (6.7)
III stage 227 (46.6) 36 (45.0) 28 (46.7)
IV stage 160 (32.9) 32 (40.0) 28 (46.7)
Radiotherapy
IMRT 294 (60.4) 72 (90.0) 60 (100.0)
Three-dimensional RT 47 (9.7) 2 (2.5) 0 (0.0)
Conventional RT 86 (17.7) 4 (5.0) 0 (0.0)
No 60 (12.3) 2 (2.5) 0 (0.0)
Other disease
Yes 98 (20.1) 60 (75.0) 47 (78.3)
No 389 (79.9) 20 (25.0) 13 (21.7)
aThe patients were used for the retest test
bThe patients were used for the responsiveness test
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completion of RT, all domain scores decreased (Table 6).
The score changes for all domains were significantly dif-
ferent, with effect sizes ranging from −0.82 (SE domain)
to −0.22 (SO domain).
Discussion
The most commonly specific instruments used to assess
QOL of NPC patients include QLQ-C30, QLQ-H&N35
[4, 32, 33], and FACT-NP, which consists of FACT-G
and NPC subscale [11]; however, due to cultural differ-
ences, we developed the QOL-NPC to assess the QOL
of Chinese NPC patients.
The QOL-NPC (V2) had good content validity accord-
ing to the suggestions of experts. The QOL-NPC was
broadly defined as the endpoint directly derived from
the patient, which included symptoms, health status, ad-
herence, and side effect [34]. The QOL-NPC included
the most important aspects characterizing specific as-
pects of NPC patients, which is structurally made up of
physical function, psychological function, social function,
and side effects. For example, physical function included
feeling tired, losing weight, having a headache, nasal
tampon or nasal bleeding, satisfied with appearance, and
coughing when swallowing food. Side effects included
Table 2 Missing data, mean and SD for each item (n = 487)
Score 1 Score 2 Score 3 Score 4 Score 5 Missing (%) Mean SD
PH1 13 92 195 170 13 4(0.8) 3.16 0.86
PH2 24 105 170 161 20 7(1.4) 3.10 0.96
PH3 28 184 191 60 10 14(2.9) 2.66 0.85
PH4 14 63 155 166 82 7(1.4) 3.50 1.02
PH5 13 40 96 209 125 4(0.8) 3.81 1.00
PH6 20 60 101 171 129 6(1.2) 3.68 1.12
PH7 14 56 83 213 117 4(0.8) 3.75 1.04
PH8 16 70 129 183 86 3(0.6) 3.52 1.05
PS1 5 30 146 236 63 7(1.4) 3.67 0.82
PS2 33 281 101 59 12 1(0.2) 2.46 0.88
PS3 48 235 64 113 23 4(0.8) 2.64 1.09
PS4 35 207 168 59 16 2(0.4) 2.62 0.91
PS5 10 26 116 293 39 3(0.6) 3.67 0.78
SO1 8 17 122 281 55 4(0.8) 3.74 0.77
SO2 5 40 86 261 92 3(0.6) 3.82 0.87
SO3 38 158 63 160 67 1(0.2) 3.12 1.23
SO4 34 217 95 107 31 3(0.6) 2.76 1.07
SO5 5 46 184 220 28 4(0.8) 3.46 0.79
SE1 32 117 182 136 17 3(0.6) 2.98 0.96
SE2 31 76 141 147 87 5(1.0) 3.38 1.14
SE3 11 41 122 205 98 10(2.1) 3.71 0.96
SE4 7 38 111 184 138 9(1.8) 3.85 0.98
SE5 11 62 105 192 105 12(2.5) 3.67 1.03
SE6 14 62 126 181 93 11(2.3) 3.58 1.04
SE7 9 55 138 168 102 15(3.1) 3.63 1.01
SE8 6 34 96 197 136 18(3.7) 3.90 0.94
PHx the xth item of the PH domain, score 1 lowest QOL, score 5 highest QOL, SD standard deviation
Table 3 Descriptive statistics and reliability of the QOL-NPC (n = 487)
Domain No. of items Mean ± SD Range of score Cronbach’s alpha Split-half coefficient ICC (95 % CI)
PH 8 60.0 ± 16.9 (6.3, 100.0) 0.80 0.83 0.87 (0.85, 0.89)
PS 5 50.3 ± 15.5 (0.0, 100.0) 0.72 0.77 0.88 (0.86, 0.90)
SO 5 59.4 ± 17.2 (0.0, 100.0) 0.76 0.81 0.82 (0.78, 0.86)
SE 8 64.5 ± 17.6 (3.1, 100.0) 0.84 0.84 0.88 (0.84, 0.92)
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dry mouth (xerostomia), pain in the throat, difficulty in
opening the mouth, memory decline, skin injuries in the
head and neck, and damaged teeth due to RT. It is well-
accepted that dry mouth is the most significant morbid-
ity during and following RT, which causes serious disor-
ders in tasting, chewing, and swallowing, as well as
sleeping disorders [35].
The QOL-NPC (V2) had good reliability and validity
based on the results of CTT. All of the domains had
moderate or high Cronbach's alpha coefficients (0.72–
0.84), and split-half reliability coefficients (0.77–0.84).
The researchers gave a positive rating for internal
consistency when Cronbach's alpha was >0.70 [25]. All
of the domains had high intra-class correlation coeffi-
cients (0.82–0.88), which indicated that the QOL-NPC
(V2) can evaluate the QOL of patients. Based on the re-
sults of CFA, RMSEA was equal to 0.097 with a 90 % CI
(0.093, 0.100); NFI, NNFI, and CFI approached 0.90. The
factor loadings of CFA were >0.47. These results showed
that the QOL-NPC had good construct validity. The cor-
responding domains of the QOL-NPC and the FACT-G
and FACT-H&N were significantly related to each other.
For example, the PH domain of the QOL-NPC had a
significantly positive correlation with physical well-being
of the FACT-G.
Table 4 Items-domains correlation analysis of QOL-NPC (n = 487)
Correlation with item Factor
loading
of CFA
PH PS SO SE
PH1 0.54 0.31 0.27 0.29 0.67
PH2 0.72 0.33 0.34 0.39 0.72
PH3 0.64 0.30 0.34 0.39 0.66
PH4 0.63 0.15 0.29 0.45 0.59
PH5 0.48 0.09 0.23 0.29 0.51
PH6 0.77 0.29 0.22 0.55 0.65
PH7 0.47 0.22 0.19 0.32 0.51
PH8 0.64 0.20 0.21 0.44 0.55
PS1 0.36 0.61 0.42 0.35 0.53
PS2 0.22 0.79 0.35 0.26 0.72
PS3 0.17 0.74 0.25 0.20 0.57
PS4 0.37 0.80 0.40 0.37 0.81
PS5 0.22 0.53 0.27 0.16 0.54
SO1 0.21 0.26 0.58 0.17 0.47
SO2 0.26 0.24 0.61 0.31 0.47
SO3 0.19 0.31 0.80 0.21 0.63
SO4 0.38 0.45 0.78 0.28 0.74
SO5 0.41 0.43 0.71 0.33 0.70
SE1 0.52 0.32 0.22 0.65 0.63
SE2 0.71 0.33 0.24 0.74 0.76
SE3 0.46 0.26 0.24 0.71 0.66
SE4 0.45 0.25 0.28 0.70 0.65
SE5 0.31 0.16 0.21 0.69 0.56
SE6 0.25 0.20 0.26 0.63 0.50
SE7 0.47 0.35 0.34 0.73 0.66
SE8 0.41 0.29 0.27 0.68 0.59
Fig. 2 Results of CFA
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The PH, PS, and SE domain of the QOL-NPC were
sensitive to discriminate the QOL of NPC patients in
different RT stages. The QOL of the NPC patients
during RT were the lowest. These results were con-
sistent with our hypothesis. It is known that RT has a
serious impact on the health status of the patients [4,
36]. All the domain scores of patients using different
RT methods were significantly different. The patients
who did not receive RT had the highest scores. The
patients who receive IMRT had the higher scores
than those receiving other RT methods. Our results
were consistent with other studies, which showed that
IMRT played a significant role in improving the QOL
of NPC patients [37, 38].
The QOL-NPC (V2) had good responsiveness based
on the results of CTT. After the newly diagnosed
NPC patients received RT treatment, they had numer-
ous side effects, especially head and neck symptoms,
such as pain in the mouth and throat, dry mouth,
and difficulties in speaking. Therefore, the domain
scores of the QOL-NPC decreased. The effect sizes of
these domains ranged from −0.82 to −0.22. The effect
sizes of the SE domain were greater than the other
domains. Similar decreases in QOL were observed in
the Quality Of Life Radiation Therapy Instrument
and the Head & Neck Module [39].
The QOL-NPC had good operability. Of the patients,
97.4 % completed the questionnaire. Most of the items
had a lower proportion of missing data. The patients
completed the QOL-NPC in an average time of 8.4 min.
There were some study limitations. (1) All of the pa-
tients in the study were enrolled from the Cancer Center
of Sun Yat-Sen University. The QOL-NPC (V2) should
be further evaluated by the data from other centers. (2)
Only 60 NPC patients were used to test the responsive-
ness of the QOL-NPC (V2). The responsiveness of the
scale should be further assessed in a larger sample of pa-
tients. (4) Some patients completed the QOL-NPC with
the help of the investigators. It was a limitation of the
study, for item explanation by a third party can generate
application bias.
Conclusions
The QOL-NPC (V2) is valid for measuring QOL with
good reliability, validity, and responsiveness. We recom-
mend the application of the QOL-NPC (V2) for measur-
ing QOL in the Chinese NPC patients.
Table 5 The domain scores (mean ± SD) of patients among different RT stages and RT method
n PH PS SO SE
RT stages
Before RT 60 65.9 ± 15.5 54.5 ± 15.8 60.8 ± 17.6 71.6 ± 17.0
During RT 171 54.0 ± 14.9 47.4 ± 13.6 58.3 ± 15.7 59.2 ± 17.9
≤1 year after RT 145 59.3 ± 14.2 48.5 ± 16.5 57.5 ± 15.6 62.6 ± 16.3
~5 years after RT 65 63.5 ± 14.1 55.1 ± 16.3 63.8 ± 17.6 70.5 ± 15.9
>5 years after RT 46 72.3 ± 17.4 54.3 ± 14.7 61.3 ± 24.2 73.0 ± 15.4
P-value <0.001 <0.001 0.100 <0.001
RT method
IMRT 294 61.3 ± 15.7 51.5 ± 15.2 61.8 ± 16.4 66.8 ± 16.7
Three-dimensional RT 46 56.8 ± 13.2 44.5 ± 14.1 56.7 ± 17.1 60.6 ± 17.5
Conventional RT 86 53.4 ± 16.1 46.3 ± 15.6 51.8 ± 17.7 53.9 ± 16.6
No RT 60 65.9 ± 15.5 54.5 ± 15.8 60.8 ± 17.6 71.6 ± 17.0
P-value <0.001 <0.001 <0.001 <0.001
RT radiotherapy, IMRT intensity-modulated radiotherapy
Table 6 Change in scores and effect size from baseline to the end of radiotherapy (n = 60)
Baseline score Change scoresa 95 % CI of change scores Effect sizeb
PH 65.9 ± 15.5 −4.9 ± 6.4 (3.2, 6.5) −0.31
PS 54.5 ± 15.8 −3.8 ± 5.3 (2.4, 5.2) −0.24
SO 60.8 ± 17.6 −3.9 ± 6.0 (2.4, 5.5) −0.22
SE 71.6 ± 17.0 −5.9 ± 5.4 (4.5, 7.3) −0.82
Change scoresa, the score at the end of radiotherapy minus the baseline, −100 (maximum worsening) to +100 (maximum improvement)
Effect sizeb, calculated as the change in scores divided by the SD of the baseline score
Su et al. Health and Quality of Life Outcomes  (2016) 14:76 Page 7 of 10
Appendix 1
Quality of life scale of nasopharyngeal carcinoma pa-
tients: The QOL-NPC (version 2).
The Quality of life scale of nasopharyngeal carcinoma pa-
tients (version 2) includes 26 items, which is presented as a
five-point scale. Please respond to each item according to
your feeling in the past 2 weeks. The following items are
about your physical function, psychological function and
social function related to nasopharyngeal carcinoma.
The following items were about the side effects due to
radiotherapy.
Abbreviations
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